CN105078998A - 抑制移植物抗宿主病的新型PKCθ的小分子抑制剂 - Google Patents
抑制移植物抗宿主病的新型PKCθ的小分子抑制剂 Download PDFInfo
- Publication number
- CN105078998A CN105078998A CN201510471935.2A CN201510471935A CN105078998A CN 105078998 A CN105078998 A CN 105078998A CN 201510471935 A CN201510471935 A CN 201510471935A CN 105078998 A CN105078998 A CN 105078998A
- Authority
- CN
- China
- Prior art keywords
- pkc
- molecule inhibitor
- pkc theta
- cell
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510471935.2A CN105078998B (zh) | 2015-08-05 | 2015-08-05 | 抑制移植物抗宿主病的PKCθ的小分子抑制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510471935.2A CN105078998B (zh) | 2015-08-05 | 2015-08-05 | 抑制移植物抗宿主病的PKCθ的小分子抑制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105078998A true CN105078998A (zh) | 2015-11-25 |
CN105078998B CN105078998B (zh) | 2017-09-19 |
Family
ID=54560930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510471935.2A Active CN105078998B (zh) | 2015-08-05 | 2015-08-05 | 抑制移植物抗宿主病的PKCθ的小分子抑制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105078998B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112118842A (zh) * | 2018-01-17 | 2020-12-22 | 明赛制药股份公司 | 用于癌症治疗的联合疗法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101296904A (zh) * | 2005-07-11 | 2008-10-29 | 德福根有限公司 | 作为激酶抑制剂的酰胺衍生物 |
-
2015
- 2015-08-05 CN CN201510471935.2A patent/CN105078998B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101296904A (zh) * | 2005-07-11 | 2008-10-29 | 德福根有限公司 | 作为激酶抑制剂的酰胺衍生物 |
Non-Patent Citations (2)
Title |
---|
刘世英等: "蛋白激酶C的抑制剂", 《科学通报》 * |
梁佩芳等: "从天然产物中寻找蛋白激酶C抑制剂的研究进展", 《中国药物化学杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112118842A (zh) * | 2018-01-17 | 2020-12-22 | 明赛制药股份公司 | 用于癌症治疗的联合疗法 |
Also Published As
Publication number | Publication date |
---|---|
CN105078998B (zh) | 2017-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Morrison et al. | Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity | |
Fan et al. | A dual PI3K/HDAC inhibitor induces immunogenic ferroptosis to potentiate cancer immune checkpoint therapy | |
Bercovici et al. | The remarkable plasticity of macrophages: a chance to fight cancer | |
Carniti et al. | Pharmacologic inhibition of JAK1/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects | |
Norde et al. | PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation | |
Linden et al. | Regulation of lymphocyte function by adenosine | |
Nicol et al. | Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours | |
Re et al. | From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential | |
Wu et al. | CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma | |
Secondini et al. | Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade | |
Todaro et al. | Chemotherapy sensitizes colon cancer initiating cells to Vγ9Vδ2 T cell-mediated cytotoxicity | |
Kim et al. | Oxaliplatin regulates myeloid‐derived suppressor cell‐mediated immunosuppression via downregulation of nuclear factor‐κB signaling | |
Chen et al. | Depleting intratumoral CD4+ CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer | |
Sayegh et al. | Complement anaphylatoxins as immune regulators in cancer | |
Li et al. | Methionine enkephalin (MENK) inhibits tumor growth through regulating CD4+ Foxp3+ regulatory T cells (Tregs) in mice | |
Eyileten et al. | Immune cells in cancer therapy and drug delivery | |
Satwani et al. | Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity | |
Cohen et al. | TNFR2: The new Treg switch? | |
Li et al. | Modulation of immune checkpoints and graft-versus-leukemia in allogeneic transplants by antagonizing vasoactive intestinal peptide signaling | |
Oh et al. | Cryopreserved human natural killer cells exhibit potent antitumor efficacy against orthotopic pancreatic cancer through efficient tumor-homing and cytolytic ability | |
Nakazawa et al. | KHYG-1 cells with EGFRvIII-specific CAR induced a pseudoprogression-like feature in subcutaneous tumours derived from glioblastoma-like cells | |
He et al. | Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti–PD-1 in Metastatic Non–Small Cell Lung Cancer | |
Slaats et al. | Adenosine A2a receptor antagonism restores additive cytotoxicity by cytotoxic T cells in metabolically perturbed tumors | |
Koh et al. | GITR agonism triggers antitumor immune responses through IL21-expressing follicular helper T cells | |
Koh et al. | Combinatorial immunotherapy with gemcitabine and ex vivo-expanded NK cells induces anti-tumor effects in pancreatic cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190906 Address after: Room 411, Building 15, No. 8, Jinfeng Road, Suzhou High-tech Zone, Jiangsu Province Patentee after: Suzhou pharos Biological Medicine Technology Co.,Ltd. Address before: 200000, room 7, building 300, Lane 802, Jinxiu Road, Shanghai, Pudong New Area Patentee before: Fan Guohuang |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200706 Address after: Room 402, building 8, 760 xinjunhuan Road, Minhang District, Shanghai, 201100 Patentee after: Anmengde Pharmaceutical Technology (Shanghai) Co.,Ltd. Address before: Room 411, Building 15, No. 8, Jinfeng Road, Suzhou High-tech Zone, Jiangsu Province Patentee before: Suzhou pharos Biological Medicine Technology Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: Room 402, building 8, 760 Xinjun Ring Road, Minhang District, Shanghai 201100 Patentee after: Aimeifei Biopharmaceutical Technology (Shanghai) Co.,Ltd. Address before: Room 402, building 8, 760 Xinjun Ring Road, Minhang District, Shanghai 201100 Patentee before: Anmengde Pharmaceutical Technology (Shanghai) Co.,Ltd. |